AtlasMedx, Incorporated
AtlasMedx, Inc is a privately held, clinical stage biopharmaceutical company focused on developing highly targeted therapeutics to treat and conquer cancer. They are advancing AMXI-5001, a first-in-class orally bioavailable, small-molecule dual PARP and microtubule polymerization inhibitor, aiming to improve outcomes and quality of life for cancer patients by targeting cellular pathways vital to carcinogenesis and drug resistance. The company emphasizes innovative cancer therapies that target well-validated pathways involved in cancer development and resistance.
Industries
Nr. of Employees
small (1-50)
AtlasMedx, Incorporated
Patents
Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
US-12145925-B2
View DetailsPhthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
US-11072600-B2
View DetailsPhthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
US-10640493-B2
View Details
Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
US-12145925-B2
View DetailsPhthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
US-11072600-B2
View DetailsPhthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer
US-10640493-B2
View DetailsProducts
Clinical-stage orally bioavailable dual DNA-repair and microtubule inhibitor (clinical candidate)
A clinical-stage orally bioavailable small-molecule candidate that combines inhibition of DNA repair enzymes with microtubule polymerization inhibition to selectively kill cancer cells and address chemotherapy resistance.
Clinical-stage orally bioavailable dual DNA-repair and microtubule inhibitor (clinical candidate)
A clinical-stage orally bioavailable small-molecule candidate that combines inhibition of DNA repair enzymes with microtubule polymerization inhibition to selectively kill cancer cells and address chemotherapy resistance.
Services
Collaborative partnerships and licensing arrangements to support discovery, development, and commercialization of oncology therapeutics.
Collaborative partnerships and licensing arrangements to support discovery, development, and commercialization of oncology therapeutics.
Expertise Areas
- Small-molecule oncology drug discovery
- Synthetic lethality therapeutic strategies
- Clinical trial management and clinical development
- Medicinal chemistry and preclinical pharmacology
Key Technologies
- Synthetic lethality approaches
- PARP (poly ADP-ribose polymerase) inhibition
- Microtubule polymerization inhibition
- Oral small-molecule formulation